ArticleExperimental brain research2026
Exploring Sevoflurane promotes hippocampal neuron mitophagy in elderly postoperative cognitive dysfunction by HSP90AA1 based on network pharmacology.
Article in Experimental brain research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
As a common anesthetic, Sevoflurane may be involved in the development of postoperative cognitive dysfunction (POCD) in the elderly. This study aims to investigate whether Sevoflurane regulates mitophagy in hippocampal neurons in elderly POCD through HSP90AA1, using a network pharmacology-based approach. Multiple databases were used to screen the common targets of Sevoflurane, mitophagy and elderly POCD, and GO and KEGG pathway enrichment analyses were performed. The protein-protein interaction network was constructed using STRING database and Cytoscape software, and the binding characteristics of Sevoflurane to the core target HSP90AA1 were verified by molecular docking and dynamics simulation. For cellular experiments, mouse hippocampal neuronal cells (HT22) were treated with Sevoflurane, and rescue experiments were performed by knocking down HSP90AA1 (sh-HSP90AA1). Cell viability, oxidative stress, mitochondrial membrane potential (MMP), the expression of mitophagy markers and cell apoptosis were evaluated by CCK8 assay, LDH release detection, ROS detection, JC-1 staining, western blot and flow cytometry. A total of 42 common targets of Sevoflurane, mitophagy and elderly POCD were screened, among which HSP90AA1 was identified as one of the key hub targets. Molecular docking showed that Sevoflurane had a stable binding ability with HSP90AA1. Cell experiments showed that Sevoflurane treatment significantly inhibited HT22 cell viability and p63 protein expression, while increased LDH release, ROS level, MMP depolarization, LC3-II/LC3-I, PINK1, Parkin, HSP90AA1 protein expression, and cell apoptosis. However, knockdown of HSP90AA1 reversed the above cell injury effects induced by Sevoflurane. Sevoflurane may promote oxidative stress, mitophagy and apoptosis of hippocampal neurons by upregulating HSP90AA1, thereby aggravating the process of POCD in the elderly. These results suggest that HSP90AA1 is a potential key target for Sevoflurane-mediated neuronal injury.
Indexed as
Identifiers
42370964What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.